Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 5/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30814154 | 1.00 | GPR139 (0.46) | GPR139UBE2NDGAT2PDE2APTGES | |
| SCHEMBL30796404 | 0.92 | PTGES (0.41) | GPR139PDE2APTGES | |
| SCHEMBL4505233 | 0.92 | PTGES (0.41) | GPR139PDE2APTGES | |
| SCHEMBL30795275 | 0.89 | PTGES (0.41) | GPR139PTGES | |
| SCHEMBL4513778 | 0.89 | PTGES (0.41) | GPR139PTGES | |
| SCHEMBL30795732 | 0.86 | PTGES (0.44) | GPR139PTGES | |
| SCHEMBL4521933 | 0.86 | PTGES (0.44) | GPR139PTGES | |
| SCHEMBL4518291 | 0.84 | PRLHR (0.38) | GPR139PTGES | |
| SCHEMBL30795188 | 0.84 | PRLHR (0.38) | GPR139PTGES | |
| SCHEMBL30794829 | 0.83 | UBE2N (0.54) | GPR139UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | KCNA7, KCNN3, KCNQ5 | GPR139 1959/4885UBE2N 2346/4885DGAT2 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.